Strategies for improving the efficacy and therapeutic ratio of glucocorticoids

详细信息	查看全文 | 推荐本文 |

• 作者：Ian M Adcock¹ ; ^{ian.adcock@imperial.ac.uk} ; Gaetano Caramori² ; Paul A Kirkham¹
• 刊名：Current Opinion in Pharmacology
• 出版年：2012
• 期刊代码：11_14714892
• 类别：pha
• 出版时间：June, 2012
• 卷：12
• 期：3
• 页码：246-251
• 文件大小：255 K

摘要

Although glucocorticoids are very effective in suppressing inflammation there is a clear clinical unmet need for new or improved glucocorticoids in patients with severe asthma and COPD. Recent developments include the targeted deposition of ultrafine glucocorticoid particles to treat small airways and the potential of novel agents that have a reduced side effect profile. Understanding the drivers of relative glucocorticoid resistance in these patients may lead to the development of newer drugs aimed at subsets of patients, for example asthmatics with high periostin levels. Alternatively, inhibitors of kinase pathways that are associated with inflammatory responses may be able to modulate glucocorticoid function and combinations of these inhibitors along with novel glucocorticoids may provide the combination therapy of the future.